Exhibit 99.3

KAMADA LTD.

CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2023

TABLE OF CONTENTS

	Page
Consolidated Statements of Financial Position	1
Consolidated Statements of Profit or Loss and Other Comprehensive Income	2
Consolidated Statements of Changes in Equity	3-5
Consolidated Statements of Cash Flows	6-7
Notes to the Interim Consolidated Financial Statements	8-14

- - - - - - - - - - -

i

KAMADA LTD.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	As of June 30,						As of December 31,
	2023			2022			2022
	Unaudited						Audited
	U.S Dollars in thousands
Assets
Current Assets
Cash and cash equivalents	$	21,788		$	29,933		$	34,258
Trade receivables, net		24,581			17,738			27,252
Other accounts  receivables		3,077			6,410			8,710
Inventories		80,237			64,520			68,785
Total Current Assets		129,683			118,601			139,005
Non-Current Assets
Property, plant and equipment, net		26,936			25,914			26,157
Right-of-use assets		5,517			2,810			2,568
Intangible assets, Goodwill and other long-term assets		143,986			150,449			147,072
Contract assets		8,267			6,361			7,577
Total Non-Current Assets		184,706			185,534			183,374
Total Assets	$	314,389		$	304,135		$	322,379
Liabilities
Current Liabilities
Current maturities of bank loans	$	4,444		$	4,449		$	4,444
Current maturities of lease liabilities		1,063			1,010			1,016
Current maturities of other long term liabilities		25,077			20,117			29,708
Trade payables		27,969			17,954			32,917
Other accounts payables		7,235			6,110			7,585
Deferred revenues		38			40			35
Total Current Liabilities		65,826			49,680			75,705
Non-Current Liabilities
Bank loans		10,741			15,185			12,963
Lease liabilities		4,972			2,492			2,177
Contingent consideration		19,028			23,121			17,534
Other long-term liabilities		36,514			41,304			37,308
Deferred revenues		0			15			-
Employee benefit liabilities, net		556			764			672
Total Non-Current Liabilities		71,811			82,881			70,654
Shareholder’s Equity
Ordinary shares		11,737			11,731			11,734
Additional paid in capital  net		210,727			210,319			210,495
Capital reserve due to translation to presentation currency		(3,490	)		(3,490	)		(3,490	)
Capital reserve from hedges		(67	)		(442	)		(88	)
Capital reserve from share-based payments		5,902			5,097			5,505
Capital reserve from employee benefits		424			271			348
Accumulated deficit		(48,481	)		(51,912	)		(48,484	)
Total Shareholder’s Equity		176,752			171,574			176,020
Total Liabilities and Shareholder’s Equity	$	314,389		$	304,135		$	322,379

The accompanying Notes are an integral part of the Consolidated Financial Statements.

1

KAMADA LTD.

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Six months period ended						Three months period ended						Year ended
	June 30,						June 30,						December 31,
	2023			2022			2023			2022			2022
	Unaudited						Unaudited						Audited
	U.S Dollars in thousands
Revenues from proprietary products	$	55,001		$	41,618		$	30,940		$	18,607		$	102,598
Revenues from distribution		13,152			10,065			6,503			4,983			26,741
Total revenues		68,153			51,683			37,443			23,590			129,339
Cost of revenues from proprietary products		30,416			24,705			17,192			12,256			58,229
Cost of revenues from distribution		11,462			8,436			5,815			4,094			24,407
Total cost of revenues		41,878			33,141			23,007			16,350			82,636
Gross profit		26,275			18,542			14,436			7,240			46,703
Research and development expenses		7,514			7,063			4,283			2,643			13,172
Selling and marketing expenses		7,862			6,592			3,940			3,271			15,284
General and administrative expenses		6,902			6,316			3,484			3,311			12,803
Other expenses		1,077			619			98			309			912
Operating income (loss)		2,920			(2,048	)		2,631			(2,294	)		4,532
Financial income		25			3			-			1			91
Income (expenses) in respect of currency exchange differences and derivatives instruments, net		173			593			22			424			298
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.		(2,070	)		(3,875	)		(309	)		(1,865	)		(6,266	)
Financial expenses		(939	)		(372	)		(439	)		(178	)		(914	)
Income (expense) before tax on income		109			(5,699	)		1,905			(3,912	)		(2,259	)
Taxes on income		106			50			93			9			62
Net Income (loss)	$	3		$	(5,749	)	$	1,812		$	(3,921	)	$	(2,321	)
Other Comprehensive Income (loss) :
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met:
Gain (loss) on cash flow hedges		(244	)		(784	)		(88	)		(676	)		(776	)
Net amounts transferred to the statement of profit or loss for cash flow hedges		265			288			120			222			634
Items that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain (loss) from defined benefit plan		76			420			(115	)		420			497
Tax effect		-			-			-			-			-
Total comprehensive income (loss)	$	100		$	(5,825	)	$	1,729		$	(3,955	)	$	(1,966	)
Earnings per share attributable to equity holders of the Company:
Basic net earnings per share	$	0.00		$	(0.13	)	$	0.04		$	(0.09	)	$	(0.05	)
Diluted net earnings per share	$	0.00		$	(0.13	)	$	0.04		$	(0.09	)	$	(0.05	)

The accompanying Notes are an integral part of the Consolidated Financial Statements.

2

KAMADA LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Share		Additional paid in		Capital reserve due to translation to presentation			Capital reserve from			Capital reserve from sharebased			Capital reserve from employee		Accumulated			Total
	capital		capital		currency			hedges			payments			benefits		deficit			equity
	Unaudited
	U.S Dollars in thousands
Balance as of January 1, 2023 (audited)	$	11,734	$	210,495	$	(3,490	)	$	(88	)	$	5,505		$	348	$	(48,484	)	$	176,020
Net income		-		-		-			-			-			-		3			3
Other comprehensive income (loss)		-		-		-			21			-			76		-			97
Tax effect		-		-		-			-			-			-		-			-
Total comprehensive income (loss)		-		-		-			21			-			76		3			100
Exercise and forfeiture of share-based payment into shares		3		232		-			-			(232	)		-		-			3
Cost of share-based payment		-		-		-			-			629			-		-			629
Balance as of June 30, 2023	$	11,737	$	210,727	$	(3,490	)	$	(67	)	$	5,902		$	424	$	(48,481	)	$	176,752

	Share		Additional paid in		Capital reserve due to translation to presentation			Capital reserve from			Capital reserve from sharebased			Capital reserve from employee			Accumulated			Total
	capital		capital		currency			hedges			payments			benefits			deficit			equity
	Unaudited
	U.S Dollars in thousands
Balance as of January 1, 2022 (audited)	$	11,725	$	210,204	$	(3,490	)	$	54		$	4,643		$	(149	)	$	(46,163	)	$	176,824
Net income		-		-		-			-			-			-			(5,749	)		(5,749	)
Other comprehensive income (loss)		-		-		-			(496	)		-			420			-			(76	)
Tax effect		-		-		-			-			-			-			-			-
Total comprehensive income (loss)		-		-		-			(496	)		-			420			(5,749	)		(5,825	)
Exercise and forfeiture of share-based payment into shares		6		115		-			-			(115	)		-			-			6
Cost of share-based payment		-		-		-			-			504			-			-			504
Balance as of June 30, 2022	$	11,731	$	210,319	$	(3,490	)	$	(442	)	$	5,097		$	271		$	(51,912	)	$	171,574

The accompanying Notes are an integral part of the Consolidated Financial Statements.

3

KAMADA LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Share		Additional paid in		Capital reserve due to translation to presentation			Capital reserve from			Capital reserve from sharebased			Capital reserve from employee			Accumulated			Total
	capital		capital		currency			hedges			payments			benefits			deficit			equity
	Unaudited
	U.S Dollars in thousands
Balance as of April 1, 2023 (Audited)	$	11,736	$	210,665	$	(3,490	)	$	(99	)	$	5750		$	539		$	(50,293	)	$	174,808
Net income		-		-		-			-			-			-			1,812			1,812
Other comprehensive income (loss)		-		-		-			32			-			(115	)		-			(83	)
Tax effect		-		-		-			-			-			-			-			-
Total comprehensive income (loss)		-		-		-			32			-			(115	)		1,812			1,729
Exercise and forfeiture of share-based payment into shares		1		62		-			-			(62	)		-			-			1
Cost of share-based payment		-		-		-			-			214			-			-			214
Balance as of June 30, 2023	$	11,737	$	210,727	$	(3,490	)	$	(67	)	$	5,902		$	424		$	(48,481	)	$	176,752

	Share capital		Additional paid in capital		Capital reserve due to translation to presentation currency			Capital reserve from hedges			Capital reserve from sharebased payments			Capital reserve from employee benefits			Accumulated deficit			Total equity
	Unaudited
	U.S Dollars in thousands
Balance as of April 1, 2022 (Audited)	$	11,728	$	210,269	$	(3,490	)	$	12		$	4,771		$	(149	)	$	(47,991	)	$	175,150
Net income		-		-		-			-			-			-			(3,921	)		(3,921	)
Other comprehensive income (loss)		-		-		-			(454	)		-			420			-			(34	)
Taxes effect		-		-		-			-			-			-			-			-
Total comprehensive income (loss)		-		-		-			(454	)		-			420			(3,921	)		(3,955	)
Exercise and forfeiture of share-based payment into shares		3		50		-			-			(50	)		-			-			3
Cost of share-based payment		-		-		-			-			376			-			-			376
Balance as of June 30, 2022	$	11,731	$	210,319	$	(3,490	)	$	(442	)	$	5,097		$	271		$	(51,912	)	$	171,574

The accompanying Notes are an integral part of the Consolidated Financial Statements.

4

KAMADA LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Share capital		Additional paid in capital		Capital reserve due to translation to presentation currency			Capital reserve from hedges			Capital reserve from sharebased payments			Capital reserve from employee benefits			Accumulated deficit			Total equity
	Audited
	U.S Dollars in thousands
Balance as of January 1, 2022 (audited)	$	11,725	$	210,204	$	(3,490	)	$	54		$	4,643		$	(149	)	$	(46,163	)	$	176,824
Net income		-		-		-			-			-			-			(2,321)			(2,321	)
Other comprehensive income (loss)		-		-		-			(142	)		-			497			-			355
Taxes effect		-		-		-			-			-			-			-			-
Total comprehensive income (loss)		-		-		-			(142	)		-			497			(2,321	)		(1,966	)
Exercise and forfeiture of share-based payment into shares		9		291		-			-			(291	)					-			9
Cost of share-based payment		-		-		-			-			1,153						-			1,153
Balance as of December 31, 2022	$	11,734	$	210,495	$	(3,490	)	$	(88	)	$	5,505		$	348		$	(48,484	)	$	176,020

The accompanying Notes are an integral part of the Consolidated Financial Statements.

5

KAMADA LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months period Ended						Three months period Ended						Year Ended
	June, 30						June, 30						December 31,
	2023			2022			2023			2022			2022
	Unaudited												Audited
	U.S Dollars in thousands
Cash Flows from Operating Activities
Net income (loss)	$	3		$	(5,749	)	$	1,812		$	(3,921	)	$	(2,321	)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Adjustments to the profit or loss items:
Depreciation and impairment		6,327			6,088			3,204			3,061			12,155
Financial expenses (income), net		2,811			3,651			726			1,618			6,791
Cost of share-based payment		629			569			214			376			1,153
Taxes on income		106			50			93			9			62
Loss (gain) from sale of property and equipment		(5	)		-			-			-			-
Change in employee benefit liabilities, net		(40	)		(96	)		(32	)		(84	)		(111	)
		9,828			10,262			4,205			4,980			20,050
Changes in asset and liability items:
Decrease (increase) in trade receivables, net		2,696			17,102			(3,610	)		3,610			7,603
Decrease (increase) in other accounts receivables		1,539			2,073			177			1,484			(578	)
Decrease (increase) in inventories		(11,452	)		2,903			(482	)		241			(1,361	)
Decrease (increase) in deferred expenses		3,042			(484	)		(512	)		(374	)		(1,340	)
Increase (decrease) in trade payables		(5,436	)		(7,843	)		1,276			5,806			7,055
Increase (decrease) in other accounts payables		(408	)		(1,517	)		(170	)		(745	)		290
Decrease in deferred revenues		3			-			(381	)		-			(20	)
		(10,016	)		12,234			(3,702	)		10,022			11,649
Cash received (paid) during the period for:
Interest paid		(744	)		(380	)		(403	)		(186	)		(853	)
Interest received		25			3			0			1			97
Taxes paid		(112	)		(18	)		(94	)		(9	)		(36	)
		(831	)		(395	)		(497	)		(194	)		(792	)
Net cash provided by (used in) operating activities	$	(1,016	)	$	16,352		$	1,818		$	10,887		$	28,586

6

KAMADA LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months period Ended						Three months period Ended						Year Ended
	June, 30						June, 30						December 31,
	2023			2022			2023			2022			2022
	Unaudited												Audited
	U.S Dollars In thousands
Cash Flows from Investing Activities
Purchase of property and equipment and intangible assets	$	(2,147	)	$	(1,191	)	$	(1,048	)	$	(678	)	$	(3,784	)
Proceeds from sale of property and equipment		6			-			-			-			-
Business combination		-			-			-			-			-
Net cash provided by (used in) investing activities		(2,141	)		(1,191	)		(1,048	)		(678	)		(3,784	)
Cash Flows from Financing Activities
Proceeds from exercise of share base payments		3			6			2			3			9
Receipt of long-term loans		-			-			-			-			-
Repayment of lease liabilities		(517	)		(573	)		(246	)		(278	)		(1,098	)
Repayment of long-term loans		(2,222	)		(401	)		(1,111	)		(385	)		(2,628	)
Repayment of other long-term liabilities		(6,000	)		(3,243	)		(4,500	)		(1,743	)		(5,626	)
Net cash provided by (used in) financing activities		(8,736	)		(4,211	)		(5,855	)		(2,403	)		(9,343	)
Exchange differences on balances of cash and cash equivalent		(577	)		396			(248	)		160			212
Increase (decrease) in cash and cash equivalents		(12,470	)		11,346			(5,333	)		7,966			15,671
Cash and cash equivalents at the beginning of the period		34,258			18,587			27,121			21,967			18,587
Cash and cash equivalents at the end of the period	$	21,788		$	29,933		$	21,788		$	29,933		$	34,258
Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability	$	3,585		$	296		$	5		$	121		$	551
Purchase of property and equipment and Intangible assets	$	840		$	775		$	840		$	775		$	618

The accompanying Notes are an integral part of the Consolidated Financial Statements.

7

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1:- General

General description of the Company and its activity

Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products CYTOGAM®, KEDRAB®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D) ® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, Middle East and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years added eleven biosimilar products to its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D). In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial.

In November 2021, the Company acquired CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM B from Saol Therapeutics Ltd. (“Saol”). The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The Company’s wholly owned U.S. subsidiary, Kamada Inc., is responsible for the commercialization of the four products in the U.S. market, including direct sales to wholesalers and local distributers. Refer to Note 5 in our annual Financial report for further details on this acquisition.

8

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 2:- Significant Accounting Policies

a. Basis of preparation of the interim consolidated financial statements:

The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”.

b. Implementation of new accounting standards:

Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current and subsequent amendment: Non-Current Liabilities with Covenants

The Amendment, together with the subsequent amendment to IAS 1 (see hereunder) replaces certain requirements for classifying liabilities as current or non-current. According to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it “has substance” and is in existence at the end of the reporting period. According to the subsequent amendment, as published in October 2022, covenants with which the entity must comply after the reporting date do not affect classification of the liability as current or non-current. Additionally, the subsequent amendment adds disclosure requirements for liabilities subject to covenants within 12 months after the reporting date, such as disclosure regarding the nature of the covenants, the date they need to be complied with and facts and circumstances that indicate the entity may have difficulty complying with the covenants. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity.

The Amendment and subsequent amendment are effective for reporting periods beginning on or after January 1, 2024 with earlier application being permitted. The Amendment and subsequent amendment are applicable retrospectively, including an amendment to comparative data.

The Company believes that the adoption of the Amendment will not have an effect on its financial statements.  

9

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 3:- Significant events in the reporting period

Grant of options to the purchase ordinary shares of the Company to employees, executive officers.

On February 27, 2023, the Company’s Board of Directors approved the grant of options to purchase up to 147,000 options to purchase ordinary shares of the Company under the 2011 Plan and the US Appendix.

The Company granted, out of the above mentioned, to employees and executive officers the following:

Under the Israeli Share Option Plan:

- On February 27, 2023, 60,331 options to purchase the ordinary shares of the Company, at an exercise price of NIS 16.53 (USD 4.50) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated at $108 thousands.

- On March 01, 2023 3,333 options to purchase ordinary shares of the Company, at an exercise price of NIS 16.63 (USD 4.57) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $5.7 thousands.

- On March 02, 2023 40,000 options to purchase ordinary shares of the Company, at an exercise price of NIS 16.76 (USD 4.60) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $71 thousands.

- On April 23, 2023 40,000 options to purchase ordinary shares of the Company, at an exercise price of NIS 17.67 (USD 4.83) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $65 thousands.

Under the US Appendix:

- On February 27, 2023 3,333 options to purchase the ordinary shares of the Company, at an exercise price of USD 4.57 per share. The fair value of the options was estimated on the date of grant was estimated at $5.80 thousands.

On May 28, 2023, the Company’s Board of Directors approved the grant of 90,000 options to purchase ordinary shares of the Company, under the Israeli Share Option Plan, at an exercise price of NIS 19.46 (USD 5.25) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $217 thousands.

10

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 4:- Operating Segments

a. General:

The company has two operating segments, as follows:

Proprietary Products	-	Development, manufacturing, sales and distribution of proprietary plasma-derived protein therapeutics.
Distribution	-	Distribute imported drug products in Israel, which are manufactured by third parties.

b. Reporting on operating segments:

	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Six months period ended June 30, 2023
Revenues	$	55,001	$	13,152	$	68,153
Gross profit	$	24,585	$	1,690	$	26,275
Unallocated corporate expenses						(23,355	)
Finance expenses, net						(2,811	)
Income before taxes on income					$	109

	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Six months period ended June 30, 2022
Revenues	$	41,618	$	10,065	$	51,683
Gross profit	$	16,913	$	1,629	$	18,542
Unallocated corporate expenses						(20,590	)
Finance expenses, net						(3,651	)
Income before taxes on income					$	(5,699	)

	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Three months period ended June 30, 2023
Revenues	$	34,940	$	6,503	$	37,443
Gross profit	$	13,748	$	688	$	14,436
Unallocated corporate expenses						(11,805	)
Finance expenses, net						(726	)
Income before taxes on income					$	1,905

	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Three months period ended June 30, 2022
Revenues	$	18,607	$	4,983	$	23,590
Gross profit	$	6,351	$	899	$	7,240
Unallocated corporate expenses						(9,534	)
Finance expenses, net						(1,618	)
Income before taxes on income					$	(3,912	)

11

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 4:- Operating Segments (cont.)

b. Reporting on operating segments:

	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Audited
Year Ended December 31, 2022
Revenues	$	102,598	$	26,741	$	129,339
Gross profit	$	44,369	$	2,334	$	46,703
Unallocated corporate expenses						(42,171	)
Finance expenses, net						(6,791	)
Income before taxes on income					$	(2,259	)

c. Reporting on operating segments by geographic region:

	Six months period ended June 30, 2023
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Geographical markets
U.S.A and North America	$	36,856	$	-	$	36,856
Israel		2,101		13,152		15,252
Europe		3,550		-		3,550
Latin America		9,931		-		9,931
Asia		2,480		-		2,480
Others		83		-		83
	$	55,001	$	13,152	$	68,153

12

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 4:- Operating Segments (cont.)

c. Reporting on operating segments by geographic region:

	Six months period ended June 30, 2022
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Geographical markets
U.S.A and North America.	$	28,562	$	-	$	28,562
Israel		2,254		10,065		12,319
Europe		5,149		-		5,149
Latin America		3,526		-		3,526
Asia		1,760		-		1,760
Others		367		-		367
	$	41,618	$	10,065	$	51,683

	Three months period ended June 30, 2023
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Geographical markets
U.S.A and North America.	$	20,026	$	-	$	20,026
Israel		1,107		6,503		7,610
Europe		216		-		216
Latin America		8,615		-		8,615
Asia		930		-		930
Others		46		-		46
	$	30,940	$	6,503	$	37,443

	Three months period ended June 30, 2022
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Unaudited
Geographical markets
U.S.A and North America.	$	11,611	$	-	$	11,611
Israel		627		4,983		5,610
Europe		4,097		-		4,097
Latin America		1,496		-		1,496
Asia		776		-		776
Others		-		-		-
	$	18,607	$	4,983	$	23,590

	Year ended December 31, 2022
	Proprietary Products		Distribution		Total
	U.S Dollars in thousands
	Audited
Geographical markets
U.S.A and North America	$	75,851	$	-	$	75,851
Israel		5,290		26,741		32,031
Europe		5,277		-		5,277
Latin America		11,293		-		11,293
Asia		4,581		-		4,581
Others		305		-		305
	$	102,597	$	26,741	$	129,338

13

KAMADA LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 5:- Financial Instruments

a. Classification of financial instruments by fair value hierarchy

Financial assets (liabilities) measured at fair value 

	Level 1		Level 2			Level 3
	U.S Dollars in thousands
June 30, 2023
Derivatives instruments	$	-	$	(72	)	$	-
Contingent consideration		-		-			(21,712	)
June 30, 2022
Derivatives instruments				(437	)
Contingent consideration	$	-	$			$	(23,121	)
December 31, 2022
Derivatives instruments	$	-	$	(92	)	$	-
Contingent consideration	$	-	$	-		$	(23,534	)

During the six months ended on June 30, 2023 there were no transfers due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument.

14